Voluntary pricing agreements with drugmakers are more effective than mandatory controls

CDC and HHS leadership, research integrity, bioethics, regulatory appointments, e-cigarette regulation, and global health funding.

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.